HK1216106A1 - 靶向切割和重組的方法和組合物 - Google Patents

靶向切割和重組的方法和組合物

Info

Publication number
HK1216106A1
HK1216106A1 HK16104006.6A HK16104006A HK1216106A1 HK 1216106 A1 HK1216106 A1 HK 1216106A1 HK 16104006 A HK16104006 A HK 16104006A HK 1216106 A1 HK1216106 A1 HK 1216106A1
Authority
HK
Hong Kong
Prior art keywords
recombination
compositions
methods
targeted cleavage
cleavage
Prior art date
Application number
HK16104006.6A
Other languages
English (en)
Inventor
Jeffrey C Miller
Lei Zhang
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Publication of HK1216106A1 publication Critical patent/HK1216106A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Processing Of Solid Wastes (AREA)
  • Fertilizers (AREA)
HK16104006.6A 2004-02-05 2016-04-07 靶向切割和重組的方法和組合物 HK1216106A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54278004P 2004-02-05 2004-02-05
US55683104P 2004-03-26 2004-03-26
US57591904P 2004-06-01 2004-06-01
US10/912,932 US7888121B2 (en) 2003-08-08 2004-08-06 Methods and compositions for targeted cleavage and recombination

Publications (1)

Publication Number Publication Date
HK1216106A1 true HK1216106A1 (zh) 2016-10-14

Family

ID=34923453

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07100975.2A HK1094009A1 (zh) 2004-02-05 2007-01-26 用於特異性切割和重組的方法及合成物
HK16104006.6A HK1216106A1 (zh) 2004-02-05 2016-04-07 靶向切割和重組的方法和組合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK07100975.2A HK1094009A1 (zh) 2004-02-05 2007-01-26 用於特異性切割和重組的方法及合成物

Country Status (7)

Country Link
US (5) US7888121B2 (zh)
EP (2) EP1720995B1 (zh)
AU (1) AU2005220148B2 (zh)
CA (1) CA2554966C (zh)
ES (1) ES2543409T3 (zh)
HK (2) HK1094009A1 (zh)
WO (1) WO2005084190A2 (zh)

Families Citing this family (463)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474486C (en) 2002-01-23 2013-05-14 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20100151556A1 (en) * 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
WO2003078619A1 (en) * 2002-03-15 2003-09-25 Cellectis Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (en) * 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
EP2559759A1 (en) 2003-01-28 2013-02-20 Cellectis Custom-made meganuclease and use thereof
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
WO2005100393A1 (en) * 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Methods and compositions for modulating cardiac contractility
US20070072815A1 (en) * 2004-05-04 2007-03-29 Kmiec Eric B Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration
US20060063231A1 (en) * 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
WO2007013979A2 (en) * 2005-07-20 2007-02-01 Invitrogen Corporation Methods for increasing efficiency of homologous recombination
WO2007014181A2 (en) * 2005-07-25 2007-02-01 Johns Hopkins University Site-specific modification of the human genome using custom-designed zinc finger nucleases
JP2009502170A (ja) * 2005-07-26 2009-01-29 サンガモ バイオサイエンシズ インコーポレイテッド 外来核酸配列の標的化された組込み及び発現
DK2662442T3 (en) 2005-10-18 2015-07-06 Prec Biosciences Rationally designed mechanuclease with altered dimer formation affinity
WO2007060495A1 (en) * 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
CA2650414A1 (en) * 2006-05-19 2007-11-29 Sangamo Biosciences, Inc. Methods and compositions for inactivation of dihydrofolate reductase
EP2447279B1 (en) 2006-05-25 2014-04-09 Sangamo BioSciences, Inc. Methods and compositions for gene inactivation
JP5266210B2 (ja) * 2006-05-25 2013-08-21 サンガモ バイオサイエンシズ インコーポレイテッド 改変開裂ハーフドメイン
US9428756B2 (en) 2006-08-11 2016-08-30 Dow Agrosciences Llc Zinc finger nuclease-mediated homologous recombination
WO2008060510A2 (en) * 2006-11-13 2008-05-22 Sangamo Biosciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
HUE029238T2 (en) * 2006-12-14 2017-02-28 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
ATE489465T1 (de) 2007-04-26 2010-12-15 Sangamo Biosciences Inc Gezielte integration in die ppp1r12c-position
EP2155873B1 (en) * 2007-05-23 2016-11-09 Sangamo BioSciences, Inc. Methods and compositions for increased transgene expression
AU2008259939B2 (en) 2007-06-01 2014-03-13 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
EP2171052B1 (en) 2007-07-12 2014-08-27 Sangamo BioSciences, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut 8) gene expression
US20090018098A1 (en) * 2007-07-13 2009-01-15 California Institute Of Technology Targeting the absence: homozygous dna deletions as signposts for cancer therapy
US20110014616A1 (en) * 2009-06-30 2011-01-20 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
EP2188384B1 (en) * 2007-09-27 2015-07-15 Sangamo BioSciences, Inc. Rapid in vivo identification of biologically active nucleases
WO2009042164A1 (en) 2007-09-27 2009-04-02 Dow Agrosciences Llc Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
WO2009054985A1 (en) 2007-10-25 2009-04-30 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
CA2703079A1 (en) * 2007-12-07 2009-06-18 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome
WO2009114321A2 (en) * 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
ES2459880T3 (es) 2008-04-14 2014-05-12 Sangamo Biosciences, Inc. Construcciones donantes lineales para integración dirigida
CA2722797A1 (en) * 2008-04-28 2009-11-05 Precision Biosciences, Inc. Fusion molecules of rationally-designed dna-binding proteins and effector domains
AU2009260888B2 (en) 2008-05-28 2014-09-11 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
US8597912B2 (en) 2008-06-10 2013-12-03 Sangamo Biosciences, Inc. Methods and compositions for generation of Bax-and Bak-deficient cell lines
MY160435A (en) * 2008-06-12 2017-03-15 Univ Putra Malaysia A novel antiviral peptide against avian influenza virus h9n2
DK2313498T3 (en) * 2008-07-14 2017-05-22 Prec Biosciences Inc RECOGNITION SEQUENCES FOR I-CREI-DERIVED MECHANUCLEASES AND APPLICATIONS THEREOF
CN102123778B (zh) * 2008-08-14 2014-10-29 李伟德 利用离心力的动态过滤装置
KR20160015400A (ko) 2008-08-22 2016-02-12 상가모 바이오사이언스 인코포레이티드 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
EP2180058A1 (en) * 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system
AU2009311697B2 (en) 2008-10-29 2014-12-18 Sangamo Therapeutics, Inc. Methods and compositions for inactivating glutamine synthetase gene expression
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110016542A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Canine genome editing with zinc finger nucleases
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
WO2010065123A1 (en) 2008-12-04 2010-06-10 Sangamo Biosciences, Inc. Genome editing in rats using zinc-finger nucleases
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110023157A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Equine genome editing with zinc finger nucleases
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
US20110023159A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Ovine genome editing with zinc finger nucleases
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
CA2747124C (en) * 2008-12-17 2018-09-04 Dow Agrosciences Llc Targeted integration into the zp15 locus
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
JP5827132B2 (ja) 2009-02-04 2015-12-02 サンガモ バイオサイエンシズ インコーポレイテッド ニューロパチーを治療するための方法および組成物
EP2408921B1 (en) * 2009-03-20 2017-04-19 Sangamo BioSciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
WO2010117464A1 (en) 2009-04-09 2010-10-14 Sangamo Biosciences, Inc. Targeted integration into stem cells
US8772008B2 (en) * 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
US20120171771A1 (en) 2009-07-08 2012-07-05 Cellular Dynamics International, Inc. Modified ips cells having a mutant form of a human immunodeficiency virus (hiv) cellular entry gene
JP5866283B2 (ja) 2009-07-28 2016-02-17 サンガモ バイオサイエンシーズ， インコーポレイテッド トリヌクレオチド反復疾患を治療するための方法および組成物
KR102262704B1 (ko) 2009-08-11 2021-06-09 상가모 테라퓨틱스, 인코포레이티드 표적화 변형에 대한 동형접합성 유기체
UA109418C2 (uk) 2009-10-22 2015-08-25 Конструйований білок з цинковими пальцями, направлений на гени рослин, залучені до біосинтезу жирних кислот
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
WO2011090804A1 (en) * 2010-01-22 2011-07-28 Dow Agrosciences Llc Targeted genomic alteration
WO2011097036A1 (en) 2010-02-08 2011-08-11 Sangamo Biosciences, Inc. Engineered cleavage half-domains
EP2534163B1 (en) 2010-02-09 2015-11-04 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
EP2550358A1 (en) 2010-03-22 2013-01-30 Philip Morris Products S.A. Modifying enzyme activity in plants
JP5952263B2 (ja) 2010-04-26 2016-07-13 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガーヌクレアーゼを使ったｒｏｓａ遺伝子座のゲノム編集
WO2011139349A1 (en) 2010-05-03 2011-11-10 Sangamo Biosciences, Inc. Compositions for linking zinc finger modules
CN103025344B (zh) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 新型dna-结合蛋白及其用途
US20110201118A1 (en) * 2010-06-14 2011-08-18 Iowa State University Research Foundation, Inc. Nuclease activity of tal effector and foki fusion protein
JP6050230B2 (ja) 2010-07-21 2016-12-21 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｈｌａ遺伝子座の修飾のための方法及び組成物
JP2013537410A (ja) 2010-07-23 2013-10-03 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー 標的化エンドヌクレアーゼおよび一本鎖核酸を用いたゲノム編集
US9057057B2 (en) * 2010-07-27 2015-06-16 The Johns Hopkins University Obligate heterodimer variants of foki cleavage domain
US9566352B2 (en) 2010-09-27 2017-02-14 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
ES2562421T3 (es) 2010-10-12 2016-03-04 The Children's Hospital Of Philadelphia Métodos y composiciones para tratar la hemofilia B
US20120214241A1 (en) * 2010-12-22 2012-08-23 Josee Laganiere Zinc finger nuclease modification of leucine rich repeat kinase 2 (lrrk2) mutant fibroblasts and ipscs
CA2821547A1 (en) 2010-12-29 2012-07-05 Sigma-Aldrich Co. Llc Cells having disrupted expression of proteins involved in adme and toxicology processes
US9267123B2 (en) 2011-01-05 2016-02-23 Sangamo Biosciences, Inc. Methods and compositions for gene correction
KR20120096395A (ko) 2011-02-22 2012-08-30 주식회사 툴젠 뉴클레아제에 의해 유전자 변형된 세포를 농축시키는 방법
EP2694554A1 (en) 2011-04-08 2014-02-12 Gilead Biologics, Inc. Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
CN103492578B (zh) 2011-04-27 2016-10-19 阿迈瑞斯公司 用于基因组修饰的方法
BR112013033448B1 (pt) 2011-06-30 2022-01-25 Sigma-Aldrich Co. Llc Método para produzir uma proteína recombinante com um padrão de glicosilação semelhante ao de humano
CA2841541C (en) 2011-07-25 2019-11-12 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
MX365219B (es) * 2011-07-27 2019-05-27 The Broad Inst Inc Star Uso de una composición en un método para inhibir el crecimiento del carcinoma de células escamosas de cabeza y cuello (hnscc).
WO2013019745A1 (en) * 2011-07-29 2013-02-07 Georgia Health Sciences University Methods and compositions for genetically modifiying cells
BR112014002622A2 (pt) * 2011-08-03 2019-09-24 Du Pont método para introduzir no genoma de uma célula vegetal um sítio alvo para a integração específica de sítio, célula vegetal, parte de planta, planta ou semente, método para integrar um polinucleotídeo de interesse em um sítio alvo no genoma de uma célula vegetal
SG10201811736QA (en) 2011-09-21 2019-02-27 Sangamo Therapeutics Inc Methods and compositions for regulation of transgene expression
WO2013063315A2 (en) 2011-10-27 2013-05-02 Sangamo Biosciences, Inc. Methods and compositions for modification of the hprt locus
JP6144691B2 (ja) 2011-11-16 2017-06-07 サンガモ セラピューティクス， インコーポレイテッド 修飾されたｄｎａ結合タンパク質およびその使用
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013101877A2 (en) 2011-12-29 2013-07-04 Iowa State University Research Foundation, Inc. Genetically modified plants with resistance to xanthomonas and other bacterial plant pathogens
ES2733248T3 (es) 2012-01-11 2019-11-28 Sigma Aldrich Co Llc Producción de proteínas recombinantes con glicoformas simples
EP2809144B1 (en) 2012-02-01 2019-11-13 Dow AgroSciences LLC Novel class of glyphosate resistance genes
EP2820159B1 (en) 2012-02-29 2019-10-23 Sangamo Therapeutics, Inc. Methods and compositions for treating huntington's disease
US20130280222A1 (en) 2012-04-18 2013-10-24 Board Of Regents Of The University Of Texas System Non-disruptive gene targeting
SG11201406547YA (en) 2012-04-25 2014-11-27 Regeneron Pharma Nuclease-mediated targeting with large targeting vectors
KR102091298B1 (ko) 2012-05-02 2020-03-19 다우 아그로사이언시즈 엘엘씨 말산 탈수소효소의 표적화된 변형
JP6559063B2 (ja) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物
WO2013169398A2 (en) 2012-05-09 2013-11-14 Georgia Tech Research Corporation Systems and methods for improving nuclease specificity and activity
EP2861737B1 (en) 2012-06-19 2019-04-17 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
EP2872154B1 (en) 2012-07-11 2017-05-31 Sangamo BioSciences, Inc. Methods and compositions for delivery of biologics
EP3444342B1 (en) 2012-07-11 2020-05-27 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
KR102474010B1 (ko) 2012-08-29 2022-12-02 상가모 테라퓨틱스, 인코포레이티드 유전적 병태를 치료하기 위한 방법 및 조성물
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
UA118090C2 (uk) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
US9914930B2 (en) 2012-09-07 2018-03-13 Dow Agrosciences Llc FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
JP6401704B2 (ja) 2012-10-10 2018-10-10 サンガモ セラピューティクス， インコーポレイテッド Ｔ細胞を修飾する化合物およびその使用
US20140120578A1 (en) 2012-11-01 2014-05-01 Medicago Inc. Plants for production of therapeutic proteins
AU2013355327A1 (en) 2012-12-05 2015-06-11 Sangamo Therapeutics, Inc. Methods and compositions for regulation of metabolic disorders
RU2015128052A (ru) 2012-12-13 2017-01-19 Дау Агросайенсиз Ллс Точный таргетинг генов в отношении конкретного локуса кукурузы
CN105120656A (zh) 2012-12-21 2015-12-02 塞尔克蒂斯股份有限公司 冷诱导甜味降低的马铃薯
CN104995302B (zh) 2013-01-16 2021-08-31 爱默蕾大学 Cas9-核酸复合物及其相关用途
MX2015010841A (es) 2013-02-20 2016-05-09 Regeneron Pharma Modificacion genetica de ratas.
JP6491113B2 (ja) 2013-02-25 2019-03-27 サンガモ セラピューティクス， インコーポレイテッド ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
JP6392315B2 (ja) 2013-03-14 2018-09-19 イミュソフト コーポレーション インビトロでのメモリーｂ細胞分化方法およびｖｓｖ−ｇ偽型ウイルスベクターを用いる形質導入方法
US10113162B2 (en) 2013-03-15 2018-10-30 Cellectis Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
CA2906970C (en) 2013-03-21 2021-05-18 Ospedale San Raffaele Srl Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
EP2981166B1 (en) 2013-04-05 2020-09-09 Dow AgroSciences LLC Methods and compositions for integration of an exogenous sequence within the genome of plants
DK2986729T3 (en) 2013-04-16 2018-10-29 Regeneron Pharma TARGETED MODIFICATION OF ROOT THROUGH
CA2910427C (en) 2013-05-10 2024-02-20 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2014186469A2 (en) 2013-05-14 2014-11-20 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3730615A3 (en) 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
WO2015017866A1 (en) 2013-08-02 2015-02-05 Enevolv, Inc. Processes and host cells for genome, pathway, and biomolecular engineering
JP6588438B2 (ja) * 2013-08-28 2019-10-09 サンガモ セラピューティクス， インコーポレイテッド Ｄｎａ結合ドメインと切断ドメインとを連結するための組成物
CA2922823C (en) 2013-09-04 2023-01-17 Dow Agrosciences Llc Rapid targeting analysis in crops for determining donor insertion
CN105899665B (zh) 2013-10-17 2019-10-22 桑格摩生物科学股份有限公司 用于核酸酶介导的基因组工程改造的递送方法和组合物
CA2926078C (en) 2013-10-17 2021-11-16 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
TWI721478B (zh) 2013-11-04 2021-03-11 美商陶氏農業科學公司 最適玉米基因座（二）
EP3065540B1 (en) 2013-11-04 2021-12-15 Corteva Agriscience LLC Optimal maize loci
EP3066202B1 (en) 2013-11-04 2021-03-03 Dow AgroSciences LLC Optimal soybean loci
TWI659103B (zh) 2013-11-04 2019-05-11 陶氏農業科學公司 最適大豆基因座（二）
US10369201B2 (en) 2013-11-11 2019-08-06 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
SI3068881T1 (sl) 2013-11-13 2019-05-31 Children's Medical Center Corporation Z nukleazo posredovano uravnavanje izražanja genov
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
CA2930590C (en) * 2013-11-15 2021-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineering neural stem cells using homologous recombination
JP6535684B2 (ja) 2013-12-09 2019-06-26 サンガモ セラピューティクス， インコーポレイテッド ゲノム操作のための方法および組成物
EP3460063B1 (en) 2013-12-11 2024-03-13 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
RU2685914C1 (ru) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
JP2017505756A (ja) 2013-12-13 2017-02-23 ザ ジェネラル ホスピタル コーポレイション 可溶性高分子量（ｈｍｗ）タウ種およびその用途
AU2014368982B2 (en) 2013-12-19 2021-03-25 Amyris, Inc. Methods for genomic integration
UY35928A (es) 2013-12-31 2015-07-31 Dow Agrosciences Llc ?GEN Rf3 RESTAURADOR DE LA ANDROESTERILIDAD CITOPLASMÁTICA (CMS) TIPO S?.
US10774338B2 (en) 2014-01-16 2020-09-15 The Regents Of The University Of California Generation of heritable chimeric plant traits
PL3102673T3 (pl) 2014-02-03 2020-11-02 Sangamo Therapeutics, Inc. Sposoby i kompozycje do leczenia talasemii beta
CA2939942A1 (en) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration
ES2797050T3 (es) 2014-03-04 2020-12-01 Sigma Aldrich Co Llc Células virales resistentes y sus usos
WO2015143046A2 (en) 2014-03-18 2015-09-24 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
CN106460009A (zh) 2014-03-21 2017-02-22 小利兰·斯坦福大学托管委员会 无核酸酶的基因组编辑
US10507232B2 (en) 2014-04-02 2019-12-17 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
CA2946385A1 (en) 2014-04-22 2015-10-29 Q-State Biosciences, Inc. Diagnostic methods for neuronal disorders
WO2015164748A1 (en) 2014-04-24 2015-10-29 Sangamo Biosciences, Inc. Engineered transcription activator like effector (tale) proteins
WO2015171932A1 (en) 2014-05-08 2015-11-12 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
WO2015175642A2 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
AU2015266770A1 (en) 2014-05-30 2016-12-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods of delivering treatments for latent viral infections
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
KR102374379B1 (ko) 2014-06-06 2022-03-17 리제너론 파마슈티칼스 인코포레이티드 표적화된 좌를 변형시키는 방법 및 조성물
CA2952906A1 (en) 2014-06-20 2015-12-23 Cellectis Potatoes with reduced granule-bound starch synthase
EP3155099B1 (en) 2014-06-23 2018-03-21 Regeneron Pharmaceuticals, Inc. Nuclease-mediated dna assembly
ES2901074T3 (es) 2014-06-26 2022-03-21 Regeneron Pharma Métodos y composiciones para modificaciones genéticas objetivo y métodos de uso
CA2954201A1 (en) 2014-07-08 2016-01-14 Vib Vzw Means and methods to increase plant yield
EP3169778B1 (en) 2014-07-14 2023-10-25 Washington State University Nanos knock-out that ablates germline cells
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
US9757420B2 (en) 2014-07-25 2017-09-12 Sangamo Therapeutics, Inc. Gene editing for HIV gene therapy
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
JP6598860B2 (ja) 2014-08-06 2019-10-30 カレッジ オブ メディシン ポチョン チャ ユニバーシティ インダストリー−アカデミック コーオペレイション ファウンデーション Ｈｌａをコードする遺伝子のヌクレアーゼ媒介編集により作製される免疫適合性細胞
EP3878948A1 (en) 2014-09-16 2021-09-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
MX2017004890A (es) 2014-10-15 2018-02-12 Regeneron Pharma Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
US11352666B2 (en) 2014-11-14 2022-06-07 Institute For Basic Science Method for detecting off-target sites of programmable nucleases in a genome
CN113016720B (zh) 2014-11-24 2023-02-21 瑞泽恩制药公司 表达人源化cd3复合物的非人类动物
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
MX2017008190A (es) 2014-12-19 2018-03-23 Regeneron Pharma Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa.
US10190106B2 (en) 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
EP3247366A4 (en) 2015-01-21 2018-10-31 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
SG11201706041XA (en) 2015-01-26 2017-08-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
US10048275B2 (en) 2015-03-13 2018-08-14 Q-State Biosciences, Inc. Cardiotoxicity screening methods
WO2016161446A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
US10738290B2 (en) 2015-04-21 2020-08-11 Novartis Ag RNA-guided gene editing system and uses thereof
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
SG10202112057QA (en) 2015-05-12 2021-12-30 Sangamo Therapeutics Inc Nuclease-mediated regulation of gene expression
US10288863B2 (en) 2015-05-21 2019-05-14 Q-State Biosciences, Inc. Optogenetics microscope
US20160346360A1 (en) 2015-05-29 2016-12-01 Agenovir Corporation Compositions and methods for cell targeted hpv treatment
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
US11612149B2 (en) 2015-07-10 2023-03-28 Chugai Seiyaku Kabushiki Kaisha Non-human animal having human CD3 gene substituted for endogenous CD3 gene
CA2991301A1 (en) 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
EP4361279A2 (en) 2015-08-06 2024-05-01 The Curators of the University of Missouri Pathogen-resistant animals having modified cd163 genes
US10837024B2 (en) 2015-09-17 2020-11-17 Cellectis Modifying messenger RNA stability in plant transformations
EP3352776A4 (en) 2015-09-23 2019-03-13 Sangamo Therapeutics, Inc. HTT REPRESSORS AND USES THEREOF
WO2017074526A1 (en) 2015-10-28 2017-05-04 Sangamo Biosciences, Inc. Liver-specific constructs, factor viii expression cassettes and methods of use thereof
US11085046B2 (en) 2015-10-29 2021-08-10 Amyris, Inc. Compositions and methods for production of myrcene
JP2018533363A (ja) 2015-11-04 2018-11-15 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
ES2953925T3 (es) 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes
CA3004349A1 (en) 2015-11-23 2017-06-01 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
IL297018A (en) 2015-12-18 2022-12-01 Sangamo Therapeutics Inc Directed cleavage of cell mhc receptor
US11352631B2 (en) 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
SG11201805680SA (en) 2016-01-15 2018-07-30 Sangamo Therapeutics Inc Methods and compositions for the treatment of neurologic disease
EP3410843A1 (en) 2016-02-02 2018-12-12 Cellectis Modifying soybean oil composition through targeted knockout of the fad3a/b/c genes
JP7012650B2 (ja) 2016-02-02 2022-01-28 サンガモ セラピューティクス， インコーポレイテッド Ｄｎａ結合ドメインと切断ドメインとを連結するための組成物
US20190249172A1 (en) 2016-02-18 2019-08-15 The Regents Of The University Of California Methods and compositions for gene editing in stem cells
WO2017161043A1 (en) 2016-03-16 2017-09-21 The J. David Gladstone Institutes Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
WO2017165655A1 (en) 2016-03-23 2017-09-28 Dana-Farber Cancer Institute, Inc. Methods for enhancing the efficiency of gene editing
US20200149038A1 (en) * 2016-04-01 2020-05-14 Children's Medical Center Corporation Methods and compositions relating to homology-directed repair
US11293033B2 (en) 2016-05-18 2022-04-05 Amyris, Inc. Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
EP3464323B1 (en) 2016-05-27 2021-09-22 Aadigen, LLC Peptides and nanoparticles for intracellular delivery of genome-editing molecules
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
KR20230088522A (ko) 2016-07-21 2023-06-19 맥스시티 인코포레이티드 게놈 dna를 변경하기 위한 방법 및 조성물
CN109803530A (zh) 2016-07-29 2019-05-24 瑞泽恩制药公司 包含引起c-截短的原纤维蛋白-1表达的突变的小鼠
US11193136B2 (en) 2016-08-09 2021-12-07 Vib Vzw Cellulose synthase inhibitors and mutant plants
JP7134944B2 (ja) 2016-08-11 2022-09-12 ザ ジャクソン ラボラトリー 遺伝子改変免疫不全非ヒト動物における改良されたヒト赤血球生存に関連する方法および組成物
EP4053146A3 (en) 2016-08-15 2022-12-07 enEvolv, Inc. Molecule sensor systems
CR20190130A (es) 2016-08-17 2019-05-07 Monsanto Technology Llc Métodos y composiciones para plantas de estatura corta a través de la manipulación del metabolismo de giberelina para aumentar el rendimiento cosechable
JP7125347B2 (ja) * 2016-08-22 2022-08-24 中外製薬株式会社 ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
IL264639B2 (en) 2016-08-24 2024-01-01 Sangamo Therapeutics Inc Regulation of globulin gene expression using transgenic nucleases with zinc neurites
BR112019003327A2 (pt) 2016-08-24 2019-07-02 Sangamo Therapeutics Inc nucleases manipuladas de alvo específico
US10960085B2 (en) 2016-09-07 2021-03-30 Sangamo Therapeutics, Inc. Modulation of liver genes
DK3757120T3 (da) 2016-10-04 2022-07-25 Prec Biosciences Inc Co-stimulerende domæner til anvendelse i genetisk modificerede celler
WO2018067826A1 (en) 2016-10-05 2018-04-12 Cellular Dynamics International, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
MA46649A (fr) 2016-10-13 2019-08-21 Juno Therapeutics Inc Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
CN110022904B (zh) 2016-10-20 2024-04-19 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
AU2017347928A1 (en) 2016-10-31 2019-05-09 Sangamo Therapeutics, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
UY37482A (es) 2016-11-16 2018-05-31 Cellectis Métodos para alterar el contenido de aminoácidos en plantas mediante mutaciones de desplazamiento de marco
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2018097257A1 (ja) 2016-11-28 2018-05-31 国立大学法人大阪大学 ゲノム編集方法
AU2017367722B2 (en) 2016-12-01 2024-02-01 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
CN110494565A (zh) 2016-12-02 2019-11-22 朱诺治疗学股份有限公司 工程化b细胞及相关组合物和方法
CA3046199A1 (en) 2016-12-08 2018-06-14 Case Western Reserve University Methods and compositions for enhancing functional myelin production
CN110582302A (zh) 2016-12-14 2019-12-17 利甘达尔股份有限公司 用于核酸和/或蛋白有效负载递送的组合物和方法
RU2019126483A (ru) 2017-01-23 2021-02-24 Ридженерон Фармасьютикалз, Инк. Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение
US20190390241A1 (en) 2017-01-24 2019-12-26 Sigma-Aldrich Co. Llc Viral resistant cells and culture systems
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
EP3583203B1 (en) 2017-02-15 2023-11-01 2seventy bio, Inc. Donor repair templates multiplex genome editing
JP2020508056A (ja) 2017-02-22 2020-03-19 クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ 遺伝子編集のための組成物および方法
CA3057289A1 (en) 2017-03-21 2018-09-27 The Jackson Laboratory A genetically modified mouse expressing human apoe4 and mouse trem2 p.r47h and methods of use thereof
AU2018260469A1 (en) 2017-04-25 2019-11-14 Cellectis Alfalfa with reduced lignin composition
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
AU2018261366A1 (en) 2017-05-03 2019-10-31 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CTFR) gene
CA3062698A1 (en) 2017-05-08 2018-11-15 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
CN110868850B (zh) 2017-05-12 2023-07-14 杰克逊实验室 缺乏i类和ii类mhc的nsg小鼠
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
MX2019013514A (es) 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
EP3635102A1 (en) 2017-06-05 2020-04-15 Regeneron Pharmaceuticals, Inc. B4galt1 variants and uses thereof
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
US11053484B2 (en) 2017-06-30 2021-07-06 Precision Biosciences, Inc. Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
NZ760841A (en) 2017-07-11 2024-02-23 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
SG11201912236YA (en) 2017-07-31 2020-01-30 Regeneron Pharma Crispr reporter non-human animals and uses thereof
CA3065579A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. Assessment of crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
MX2020001178A (es) 2017-07-31 2020-09-25 Regeneron Pharma Celulas madre embrionarias de raton transgenico con cas y ratones y usos de los mismos.
WO2019043082A1 (en) 2017-08-29 2019-03-07 Kws Saat Se BLUE ALEURONE ENHANCED AND OTHER SEGREGATION SYSTEMS
US20190098879A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
US20200239544A1 (en) 2017-10-03 2020-07-30 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
WO2019089913A1 (en) 2017-11-01 2019-05-09 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
SG11202004003YA (en) 2017-11-09 2020-05-28 Sangamo Therapeutics Inc Genetic modification of cytokine inducible sh2-containing protein (cish) gene
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3728563A4 (en) 2017-12-22 2021-11-10 Fate Therapeutics, Inc. ENHANCED IMMUNE EFFECTIVE CELLS AND THEIR USE
KR20200110687A (ko) 2018-01-17 2020-09-24 버텍스 파마슈티칼스 인코포레이티드 유전체 편집 효율을 증가시키기 위한 퀴녹살리논 화합물, 조성물, 방법 및 키트
IL276080B2 (en) 2018-01-17 2023-10-01 Vertex Pharma DNA-PK suppressor compounds, UTP-containing preparations and their uses
WO2019143675A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
AU2019218118A1 (en) 2018-02-08 2020-08-13 Sangamo Therapeutics, Inc. Engineered target specific nucleases
CA3089883A1 (en) 2018-02-15 2019-08-22 Monsanto Technology Llc Compositions and methods for improving crop yields through trait stacking
CN112041432A (zh) 2018-02-15 2020-12-04 纪念斯隆-凯特林癌症中心 Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
JP2021518160A (ja) 2018-03-15 2021-08-02 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
AU2019233929A1 (en) 2018-03-16 2020-09-24 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
KR20240038811A (ko) 2018-03-19 2024-03-25 리제너론 파마슈티칼스 인코포레이티드 CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
AU2019243315A1 (en) 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
CA3095084A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
EP3775238A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
CN112313246A (zh) 2018-04-18 2021-02-02 桑格摩生物治疗股份有限公司 用于调节亨廷顿蛋白(htt)的锌指蛋白组合物
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
GB201809273D0 (en) 2018-06-06 2018-07-25 Vib Vzw Novel mutant plant cinnamoyl-coa reductase proteins
US20210195879A1 (en) 2018-06-21 2021-07-01 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
CA3109592A1 (en) 2018-08-23 2020-02-27 Sangamo Therapeutics, Inc. Engineered target specific base editors
WO2020047282A1 (en) 2018-08-29 2020-03-05 University Of Copenhagen Lysosomal enzymes modified by cell based glycoengineering
US20210348177A1 (en) 2018-09-05 2021-11-11 The Regents Of The University Of California Generation of heritably gene-edited plants without tissue culture
CN113015741A (zh) 2018-09-18 2021-06-22 桑格摩生物治疗股份有限公司 程序性细胞死亡1(pd1)特异性核酸酶
EP3862430A4 (en) 2018-10-04 2022-06-15 Kaneka Corporation DNA CONSTRUCT FOR USE IN PLANT GENO EDITING
BR112021007229A2 (pt) 2018-10-16 2021-08-10 Blueallele, Llc métodos para inserção dirigida de dna em genes
MX2021005398A (es) 2018-11-07 2021-07-06 Crispr Therapeutics Ag Terapia del cancer con celulas inmunitarias anti-cd33.
KR20210089707A (ko) 2018-11-07 2021-07-16 크리스퍼 테라퓨틱스 아게 항-liv1 면역세포 암 치료법
KR20210092236A (ko) 2018-11-07 2021-07-23 크리스퍼 테라퓨틱스 아게 항-ptk7 면역세포 암 치료법
AU2019379576A1 (en) 2018-11-13 2021-06-03 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
EP3886869A4 (en) 2018-11-28 2022-07-06 Forty Seven, Inc. GENETICALLY MODIFIED CSPH RESISTANT TO ABLATIVE TREATMENT
CA3121781A1 (en) 2018-12-05 2020-06-11 Vertex Pharmaceuticals Incorporated Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
GB201820109D0 (en) 2018-12-11 2019-01-23 Vib Vzw Plants with a lignin trait and udp-glycosyltransferase mutation
EP3732291A1 (en) 2018-12-20 2020-11-04 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
EP3898661A1 (en) 2018-12-21 2021-10-27 Precision BioSciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
AU2020205717A1 (en) 2019-01-11 2021-08-12 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CN112805026A (zh) 2019-02-06 2021-05-14 桑格摩生物治疗股份有限公司 用于治疗i型黏多糖贮积症的方法
US20220145330A1 (en) 2019-02-10 2022-05-12 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Modified mitochondrion and methods of use thereof
CN113993375B (zh) 2019-03-26 2024-04-16 株式会社图尔金 B型血友病大鼠模型
SG11202110776TA (en) 2019-04-02 2021-10-28 Sangamo Therapeutics Inc Methods for the treatment of beta-thalassemia
AU2020256225A1 (en) 2019-04-03 2021-09-02 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
CA3135799A1 (en) 2019-04-03 2020-10-08 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
IL286917B (en) 2019-04-04 2022-09-01 Regeneron Pharma Methods for scar-free insertion of targeted modifications into targeted vectors
CA3133360A1 (en) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
WO2020206231A1 (en) 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
CN113966401A (zh) 2019-04-10 2022-01-21 犹他大学研究基金会 用于治疗amd的htra1调节
JP2022531185A (ja) 2019-04-30 2022-07-06 クリスパー セラピューティクス アクチェンゲゼルシャフト 遺伝子改変ｔ細胞を標的化するｃｄ１９を使用するｂ細胞悪性病変の同種細胞療法
BR112021021200A2 (pt) 2019-05-01 2021-12-21 Juno Therapeutics Inc Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
BR112021021075A2 (pt) 2019-05-01 2021-12-14 Editas Medicine Inc Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
EP3966334A1 (en) 2019-05-10 2022-03-16 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
CN113874510A (zh) 2019-06-04 2021-12-31 瑞泽恩制药公司 包括具有β滑移突变的人源化TTR基因座的非人动物和使用方法
KR20220017939A (ko) 2019-06-07 2022-02-14 리제너론 파마슈티칼스 인코포레이티드 인간화 알부민 좌위를 포함하는 비-인간 동물
JP2022536341A (ja) 2019-06-13 2022-08-15 アロジーン セラピューティクス，インコーポレイテッド 抗ｔａｌｅｎ抗体およびその使用
KR20220024053A (ko) 2019-06-14 2022-03-03 리제너론 파마슈티칼스 인코포레이티드 타우병증의 모델
CN114269372A (zh) 2019-06-27 2022-04-01 克里斯珀医疗股份公司 嵌合抗原受体t细胞和nk细胞抑制剂用于治疗癌症的用途
US20220273715A1 (en) 2019-07-25 2022-09-01 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
US20220267732A1 (en) 2019-08-01 2022-08-25 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
JP2022544825A (ja) 2019-08-20 2022-10-21 プレシジョン バイオサイエンシズ，インク． 細胞免疫療法のためのリンパ球枯渇投与レジメン
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP4017508A1 (en) 2019-08-23 2022-06-29 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
CN114729325A (zh) 2019-09-06 2022-07-08 克里斯珀医疗股份公司 在培养物中具有改善的持久性的基因工程化t细胞
CA3150334A1 (en) 2019-09-12 2021-03-18 Frank Meulewaeter REGULATORY NUCLEIC ACID MOLECULES TO ENHANCE GENE EXPRESSION IN PLANTS
WO2021069387A1 (en) 2019-10-07 2021-04-15 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2021072115A1 (en) 2019-10-08 2021-04-15 Regents Of The University Of Minnesota Crispr-mediated human genome editing with vectors
DK3812472T3 (da) 2019-10-21 2023-02-20 Univ Freiburg Albert Ludwigs Virkelig uvildig in vitro-undersøgelse til profilering af off-target-aktivitet af en eller flere målspecifikke programmerbare nukleaser i celler (abnoba-seq)
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
EP4051322A1 (en) 2019-11-01 2022-09-07 Sangamo Therapeutics, Inc. Compositions and methods for genome engineering
CN114746125A (zh) 2019-11-08 2022-07-12 瑞泽恩制药公司 用于x连锁青少年型视网膜劈裂症疗法的crispr和aav策略
JP7448120B2 (ja) 2019-11-14 2024-03-12 国立研究開発法人農業・食品産業技術総合研究機構 プラズマを用いてゲノム編集酵素を植物細胞内に導入する方法
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
AU2020396138A1 (en) 2019-12-03 2022-06-16 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
US20230036065A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2021158915A1 (en) 2020-02-06 2021-08-12 Precision Biosciences, Inc. Recombinant adeno-associated virus compositions and methods for producing and using the same
JP2023515671A (ja) 2020-03-04 2023-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫療法に対する腫瘍細胞の感作のための方法及び組成物
MX2022011831A (es) 2020-03-25 2023-01-04 Sana Biotechnology Inc Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas.
CA3179934A1 (en) 2020-03-26 2021-09-30 National Agriculture And Food Research Organization Method for producing temperature-sensitive male sterile plant
US20230263121A1 (en) 2020-03-31 2023-08-24 Elo Life Systems Modulation of endogenous mogroside pathway genes in watermelon and other cucurbits
JP2023525510A (ja) 2020-05-06 2023-06-16 セレクティス ソシエテ アノニム 治療用タンパク質の送達のために細胞を遺伝子改変する方法
AU2021268253A1 (en) 2020-05-06 2022-12-08 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
US20230183664A1 (en) 2020-05-11 2023-06-15 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
GB202007578D0 (en) 2020-05-21 2020-07-08 Univ Oxford Innovation Ltd Hdr enhancers
GB202007577D0 (en) 2020-05-21 2020-07-08 Oxford Genetics Ltd Hdr enhancers
WO2021234389A1 (en) 2020-05-21 2021-11-25 Oxford Genetics Limited Hdr enhancers
WO2021234388A1 (en) 2020-05-21 2021-11-25 Oxford Genetics Limited Hdr enhancers
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
AU2021308681A1 (en) 2020-07-16 2023-03-09 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2022035793A1 (en) 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
WO2022036150A1 (en) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
US20220064596A1 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
CN116322716A (zh) 2020-09-23 2023-06-23 克里斯珀医疗股份公司 Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
US20230365995A1 (en) 2020-10-07 2023-11-16 Precision Biosciences, Inc. Lipid nanoparticle compositions
MX2023004761A (es) 2020-10-23 2023-07-17 Elo Life Systems Inc Metodos para producir plantas de vainilla con mejor sabor y produccion agronomica.
US20230398148A1 (en) 2020-11-04 2023-12-14 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
EP4243609A1 (en) 2020-11-16 2023-09-20 Pig Improvement Company UK Limited Influenza a-resistant animals having edited anp32 genes
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
JP2023553419A (ja) 2020-12-03 2023-12-21 センチュリー セラピューティクス，インコーポレイテッド 遺伝子操作細胞およびその使用
US20220193134A1 (en) 2020-12-23 2022-06-23 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
JP2024501971A (ja) 2020-12-31 2024-01-17 サナ バイオテクノロジー，インコーポレイテッド Ｃａｒ－ｔ活性を調節するための方法及び組成物
WO2022165111A1 (en) 2021-01-28 2022-08-04 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
EP4305153A1 (en) 2021-03-09 2024-01-17 CRISPR Therapeutics AG Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
TW202305118A (zh) 2021-03-23 2023-02-01 美商艾歐凡斯生物治療公司 腫瘤浸潤淋巴球之ｃｉｓｈ基因編輯及其在免疫療法中之用途
CN117479952A (zh) 2021-04-07 2024-01-30 世纪治疗股份有限公司 用于嵌合抗原受体细胞的组合的人工细胞死亡/报告系统多肽及其用途
BR112023018844A2 (pt) 2021-04-07 2023-10-10 Century Therapeutics Inc Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas
CA3214473A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
US20240141311A1 (en) 2021-04-22 2024-05-02 North Carolina State University Compositions and methods for generating male sterile plants
CA3217672A1 (en) 2021-05-05 2022-11-10 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for ipsc-derived microglia
WO2022240846A1 (en) 2021-05-10 2022-11-17 Sqz Biotechnologies Company Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
WO2022251367A1 (en) 2021-05-27 2022-12-01 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
WO2022256437A1 (en) 2021-06-02 2022-12-08 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
EP4368703A1 (en) 2021-07-09 2024-05-15 Toolgen Incorporated Mesenchymal stem cell having oxidative stress resistance, preparation method therefor, and use thereof
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
CA3227357A1 (en) 2021-07-29 2023-02-02 Eun Ji Shin Hemocompatible mesenchymal stem cells, preparation method therefor and use thereof
CA3227108A1 (en) 2021-08-11 2023-02-16 Xiaomeng HU Genetically modified primary cells for allogeneic cell therapy
KR20240053673A (ko) 2021-08-11 2024-04-24 사나 바이오테크놀로지, 인크. 저면역원성 세포 내 유전자 발현을 변경하기 위한 유도성 시스템
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
AU2022326565A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
KR20240055838A (ko) 2021-09-10 2024-04-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 유도된 만능 줄기 세포 유래된 세포의 조성물 및 이의 사용 방법
WO2023042079A1 (en) 2021-09-14 2023-03-23 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
WO2023064924A1 (en) 2021-10-14 2023-04-20 Codiak Biosciences, Inc. Modified producer cells for extracellular vesicle production
CA3235185A1 (en) 2021-10-19 2023-04-27 Cassandra GORSUCH Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
WO2023070043A1 (en) 2021-10-20 2023-04-27 Yale University Compositions and methods for targeted editing and evolution of repetitive genetic elements
AU2022371442A1 (en) 2021-10-21 2024-04-18 Vertex Pharmaceuticals Incorporated Hypoimmune cells
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023077012A1 (en) 2021-10-27 2023-05-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for expressing factor ix for hemophilia b therapy
CA3235390A1 (en) 2021-10-29 2023-05-04 Deepika Rajesh Dopaminergic neurons comprising mutations and methods of use thereof
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
TW202328201A (zh) 2021-11-09 2023-07-16 美商安進公司 產生抗體肽軛合物的方法
WO2023086847A1 (en) 2021-11-10 2023-05-19 Encodia, Inc. Methods for barcoding macromolecules in individual cells
WO2023091910A1 (en) 2021-11-16 2023-05-25 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2023108047A1 (en) 2021-12-08 2023-06-15 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
WO2023105244A1 (en) 2021-12-10 2023-06-15 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
US20230346836A1 (en) 2021-12-22 2023-11-02 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023129974A1 (en) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Generation of landing pad cell lines
WO2023131616A1 (en) 2022-01-05 2023-07-13 Vib Vzw Means and methods to increase abiotic stress tolerance in plants
WO2023131637A1 (en) 2022-01-06 2023-07-13 Vib Vzw Improved silage grasses
WO2023144199A1 (en) 2022-01-26 2023-08-03 Vib Vzw Plants having reduced levels of bitter taste metabolites
US20230338477A1 (en) 2022-02-02 2023-10-26 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
WO2023150798A1 (en) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
US20230279376A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023168397A1 (en) 2022-03-04 2023-09-07 Sigma-Aldrich Co. Llc Metabolic selection via the asparagine biosynthesis pathway
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023180904A1 (en) 2022-03-21 2023-09-28 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
WO2023180967A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
WO2023180968A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023225665A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
WO2023240169A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
WO2023242827A2 (en) 2022-06-17 2023-12-21 Crispr Therapeutics Ag LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
WO2023248147A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
US20240003871A1 (en) 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof
WO2024003786A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024031053A1 (en) 2022-08-05 2024-02-08 Regeneron Pharmaceuticals, Inc. Aggregation-resistant variants of tdp-43
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024073606A1 (en) 2022-09-28 2024-04-04 Regeneron Pharmaceuticals, Inc. Antibody resistant modified receptors to enhance cell-based therapies
WO2024073692A1 (en) 2022-09-30 2024-04-04 Sigma-Aldrich Co. Llc Metabolic selection via the glycine-formate biosynthesis pathway
WO2024073686A1 (en) 2022-09-30 2024-04-04 Sigma-Aldrich Co. Llc Metabolic selection via the serine biosynthesis pathway
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024083579A1 (en) 2022-10-20 2024-04-25 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2024098002A1 (en) 2022-11-04 2024-05-10 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
WO2024103017A2 (en) 2022-11-10 2024-05-16 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466184A (en) * 1891-12-29 Fastener for the meeting-rails of sashes
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4942227A (en) 1982-01-11 1990-07-17 California Institute Of Technology Bifunctional molecules having a DNA intercalator or DNA groove binder linked to ethylene diamine tetraacetic acid, their preparation and use to cleave DNA
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4665184A (en) 1983-10-12 1987-05-12 California Institute Of Technology Bifunctional molecules having a DNA intercalator or DNA groove binder linked to ethylene diamine tetraacetic acid
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4795700A (en) 1985-01-25 1989-01-03 California Institute Of Technology Nucleic acid probes and methods of using same
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
FR2598932B1 (fr) * 1986-05-23 1988-09-02 Salomon Sa Ski profile dissymetrique
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5789155A (en) 1987-10-30 1998-08-04 California Institute Of Technology Process for identifying nucleic acids and triple helices formed thereby
EP0792931A3 (en) 1988-10-31 1999-05-19 The Regents Of The University Of California Products and methods for controlling the suppression of the neoplastic phenotype
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DE69034263D1 (de) * 1989-07-25 2009-04-02 Cell Genesys Inc Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1991006666A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5955341A (en) 1991-04-10 1999-09-21 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5916794A (en) 1992-04-03 1999-06-29 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5792640A (en) 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
DE69233416T2 (de) 1992-04-15 2005-03-03 Sembiosys Genetics Inc., Alberta Öl-körper proteine als träger von hochwertigen peptiden in pflanzen
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
JP3670003B2 (ja) 1992-06-15 2005-07-13 ファーミング ビー．ブイ． ウシ種による組み換えポリペプチドの製造及びトランスジェニック法
US5496720A (en) 1993-02-10 1996-03-05 Susko-Parrish; Joan L. Parthenogenic oocyte activation
US6331658B1 (en) 1993-04-20 2001-12-18 Integris Baptist Medical Center, Inc. Genetically engineered mammals for use as organ donors
WO1995005843A1 (en) 1993-08-25 1995-03-02 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
JP4012243B2 (ja) 1994-01-18 2007-11-21 ザ スクリップス リサーチ インスティチュート 亜鉛フィンガータンパク質誘導体およびそのための方法
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
AU698152B2 (en) 1994-08-20 1998-10-22 Gendaq Limited Improvements in or relating to binding proteins for recognition of DNA
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US6326166B1 (en) 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
WO1996040882A1 (en) 1995-06-07 1996-12-19 The Ohio State University Artificial restriction endonuclease
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6265196B1 (en) 1996-05-07 2001-07-24 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US5928914A (en) 1996-06-14 1999-07-27 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Methods and compositions for transforming cells
US5928638A (en) 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
AU8435698A (en) 1997-06-03 1998-12-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
BR9811542A (pt) 1997-07-23 2000-08-22 Roche Diagnostics Gmbh Identificação de linhas de células humanas para a produção de proteìnas humanas mediante ativação de genes endógena
US6440734B1 (en) 1998-09-25 2002-08-27 Cytomatrix, Llc Methods and devices for the long-term culture of hematopoietic progenitor cells
DE69841723D1 (de) 1997-09-26 2010-07-29 Abt Holding Co Expression von endogenen genen durch homologe rekombination eines vektorkonstruktes mit zellulärer dna
AU757930B2 (en) 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
FR2772787B1 (fr) 1997-12-24 2001-12-07 Rhone Poulenc Agrochimie Promoteur h3c4 de mais associe au premier intron de l'actine de riz, gene chimere le comprenant et plante transformee
AU2053999A (en) 1997-12-15 1999-07-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Regulatory sequences involved in pancreas-specific gene expression
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
CA2321938C (en) 1998-03-02 2009-11-24 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
EP1105472A2 (en) 1998-08-12 2001-06-13 Pangene Corporation Domain specific gene evolution
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
BR9915191A (pt) 1998-11-10 2001-12-11 Maxygen Inc Métodos para obter um polinucleotìdeo isolado epara produzir uma célula recombinante,protoplasto de célula vegetal, coleção deprotoplastos de célula vegetal, vegetal,polinucleotìdeo, biblioteca, um ou mais membros debiblioteca e célula recombinante alvo
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2000046386A2 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
AU2982300A (en) 1999-02-03 2000-08-25 Children's Medical Center Corporation Gene repair involving (in vivo) excision of targeting dna
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US6977295B2 (en) 1999-04-21 2005-12-20 Invitrogen Corporation Locked nucleic acid hybrids and methods of use
AU781628B2 (en) 1999-07-14 2005-06-02 Clontech Laboratories, Inc. Recombinase-based methods for producing expression vectors and compositions for use in practicing the same
JP3107304B1 (ja) * 1999-08-10 2000-11-06 株式会社オハラ 光フィルター用ガラスセラミックス及び光フィルター
IL150069A0 (en) 1999-12-06 2002-12-01 Sangamo Biosciences Inc Methods of using randomized libraries of zinc finger proteins for the identification of gene function
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
AU2693501A (en) 2000-01-24 2001-07-31 Gendaq Ltd Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
US7205103B2 (en) 2000-02-11 2007-04-17 The Salk Institute For Biological Studies Method of regulating transcription in a cell
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
CA2401677A1 (en) 2000-03-03 2001-09-13 University Of Utah Research Foundation Gene targeting method
DE60126483T2 (de) 2000-04-28 2007-12-06 Sangamo BioSciences, Inc., Richmond Gezielte Modifikation der Chromatinstruktur
WO2001088197A2 (en) 2000-05-16 2001-11-22 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
US6492117B1 (en) 2000-07-12 2002-12-10 Gendaq Limited Zinc finger polypeptides capable of binding DNA quadruplexes
ES2394877T3 (es) 2000-08-14 2013-02-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinación homóloga mejorada mediada por proteínas de recombinación de lambda
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US6667064B2 (en) 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
US7273923B2 (en) 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7091026B2 (en) 2001-02-16 2006-08-15 University Of Iowa Research Foundation Artificial endonuclease
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
US6395523B1 (en) * 2001-06-01 2002-05-28 New England Biolabs, Inc. Engineering nicking endonucleases from type IIs restriction endonucleases
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
WO2003027247A2 (en) * 2001-09-24 2003-04-03 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
US20060242726A1 (en) 2001-12-13 2006-10-26 Purdue Research Foundation Methods and vectors for making knockout animals
CA2474486C (en) 2002-01-23 2013-05-14 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
AU2003218382B2 (en) 2002-03-21 2007-12-13 Sangamo Therapeutics, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
AU2003298574B2 (en) 2002-09-05 2008-04-24 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
EP2559759A1 (en) 2003-01-28 2013-02-20 Cellectis Custom-made meganuclease and use thereof
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US20070113295A1 (en) 2005-09-23 2007-05-17 California Institute Of Technology Gene blocking method
DK2004827T3 (da) 2006-04-08 2010-06-14 Dsm Ip Assets Bv Forbedret fremgangsmåde til homolog rekombination i svampeceller
JP5266210B2 (ja) 2006-05-25 2013-08-21 サンガモ バイオサイエンシズ インコーポレイテッド 改変開裂ハーフドメイン
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
JP6050230B2 (ja) * 2010-07-21 2016-12-21 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｈｌａ遺伝子座の修飾のための方法及び組成物
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
WO2015136001A1 (en) 2014-03-11 2015-09-17 Cellectis Method for generating t-cells compatible for allogenic transplantation
US10975406B2 (en) 2014-07-18 2021-04-13 Massachusetts Institute Of Technology Directed endonucleases for repeatable nucleic acid cleavage
IL297018A (en) * 2015-12-18 2022-12-01 Sangamo Therapeutics Inc Directed cleavage of cell mhc receptor

Also Published As

Publication number Publication date
US20170326174A1 (en) 2017-11-16
US10675302B2 (en) 2020-06-09
US20110030076A1 (en) 2011-02-03
ES2543409T3 (es) 2015-08-19
US20140086885A1 (en) 2014-03-27
US20050064474A1 (en) 2005-03-24
AU2005220148A1 (en) 2005-09-15
WO2005084190A2 (en) 2005-09-15
AU2005220148B2 (en) 2009-12-10
HK1094009A1 (zh) 2007-03-16
EP2947146A1 (en) 2015-11-25
EP2947146B1 (en) 2017-05-31
US9782437B2 (en) 2017-10-10
EP1720995B1 (en) 2015-05-06
WO2005084190A3 (en) 2006-08-10
US20140369980A1 (en) 2014-12-18
CA2554966C (en) 2013-11-19
EP1720995A2 (en) 2006-11-15
US9289451B2 (en) 2016-03-22
US8524500B2 (en) 2013-09-03
US7888121B2 (en) 2011-02-15
EP1720995A4 (en) 2008-04-16
CA2554966A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
HK1216106A1 (zh) 靶向切割和重組的方法和組合物
HK1215046A1 (zh) 針對靶向清除和重組的方法以及組合物
HK1209729A1 (zh) 化合物、組合物和方法
AP2089A (en) Compositions and methods for combination antiviraltherapy
EP1755665A4 (en) COMPOSITIONS AND METHODS FOR MUCOSAL VACCINATION
GB0522287D0 (en) Method and compositions
EP1895838A4 (en) COMPOSITIONS AND METHODS
EP1954708A4 (en) METHODS AND COMPOSITIONS IN INTRINSIC GENES
EP1835935A4 (en) COMPOSITIONS AND METHODS FOR IMPROVED DENDRITIC CELL REPRODUCTION AND FUNCTION
IL192098A (en) Preparations and Methods for Manufacturing Preparations
HK1121952A1 (en) Methods and compositions for treating conditions
EP1718714A4 (en) COMPOSITIONS CONTAINING A PLOTTER
IL211089A0 (en) Compositions and methods for cell killing
EP1778219A4 (en) ASCOPHYLUM COMPOSITIONS AND METHODS
EP1743763A4 (en) BASIC PROTECTION METHOD
EP1763358A4 (en) COMPOSITIONS AND METHODS CUT-HUNGER
EP1773386A4 (en) VACCINE COMPOSITIONS AND CORRESPONDING METHODS
GB0524927D0 (en) Compositions and method
IL192957A0 (en) Methods and compositions for targeting relt
EP1781337A4 (en) METHODS AND COMPOSITIONS FOR CELL ACTIVATION
GB0511235D0 (en) Compositions and method
GB0501348D0 (en) Compositions and methods
HK1172260A1 (zh) 包含超分子抗原構建體的組合物和方法
ZA200704734B (en) Fuel compositions
EP1809761A4 (en) COMPOSITIONS AND METHODS FOR MODULATING DHR96